Dutasteride
Avodart
Dutasteride (Avodart) is an oral dual 5-alpha-reductase inhibitor that blocks both type 1 and type 2 isoenzymes, lowering serum dihydrotestosterone (DHT) by roughly 90-95%. It is FDA-approved for benign prostatic hyperplasia (BPH) and used off-label for male androgenetic alopecia; in physique/anti-androgen contexts it is taken to reduce DHT-driven hair loss or as an ancillary. It is not an anabolic, a SERM, or a testosterone-suppressing agent, and it does not restart the HPTA. The main risks are that (1) a subset of users develop sexual dysfunction (low libido, erectile dysfunction, reduced ejaculate) that can persist after stopping, plus reported mood changes including depression, anxiety, and suicidal ideation (the 'post-finasteride syndrome' literature applies to dutasteride as a more potent, longer-acting congener); (2) a small but statistically significant excess of high-grade (Gleason 8-10) prostate cancer and of a composite 'cardiac failure' category was seen in the 4-year REDUCE trial; (3) it is a potent teratogen — it must never be handled or used by anyone who is or may become pregnant, and it markedly suppresses PSA (~50%), which can mask prostate cancer screening. Its extremely long half-life means effects and washout extend for weeks. This is a reference summary, not medical advice; use requires a clinician and baseline/periodic bloodwork.
Mechanism of action
Pharmacokinetics
Long. Single-dose terminal half-life reported at ~7-9 days, which is why bioequivalence studies use a ~28-day washout; at steady state elimination is even slower (weeks), and low serum concentrations can persist for months after the last dose.
DHT suppression is sustained across the full daily dosing interval and persists for weeks after discontinuation because of the long half-life and tissue binding.
Oral (soft gelatin capsule), typically 0.5 mg once daily as studied in BPH, prostate-cancer prevention, and alopecia trials. Also absorbed through skin from a leaking/handled capsule.
Extensively hepatically metabolized, primarily by CYP3A4/CYP3A5, to active and inactive metabolites; excreted mainly in feces. Renal clearance of parent drug is negligible. Strong CYP3A4 inhibitors can raise exposure. This information is for monitoring and washout planning, not for evading drug testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Reduces serum DHT by roughly 90-95% within weeks of daily dosing
- Reduces total and transition-zone prostate volume and improves BPH urinary symptom scores (IPSS) and peak urinary flow (Qmax)
- Lowers the risk of acute urinary retention and BPH-related surgery over multi-year use
- Increases scalp hair count and width in male androgenetic alopecia over ~24 weeks, dose-dependently, and outperformed finasteride 1 mg on some endpoints in a head-to-head RCT
- Reduces overall biopsy-detected prostate cancer incidence (~23% relative reduction over 4 years in REDUCE)
- Lowers serum PSA by approximately 50%, altering the interpretation of prostate cancer screening
- Modest transient rise in serum testosterone (no HPTA suppression)
Adverse effects by system
A statistically significant excess of a composite 'cardiac failure' category was observed in the dutasteride arm of the 4-year REDUCE prostate-cancer prevention trial (0.7% vs 0.4% placebo, P=0.03) and as an imbalance in the CombAT combination trial. Causality is unproven and the absolute numbers are small, but the signal is real and unexplained. No consistent effect on blood pressure or lipids is established.
Extensively hepatically metabolized (CYP3A4/3A5). No meaningful hepatotoxicity signal emerged in large multi-year RCTs. There are no adequate data in severe hepatic impairment, where exposure would be expected to rise; caution and specialist input are warranted.
Not an HPTA suppressant. Serum DHT falls ~90-95% while testosterone rises transiently/modestly. Endocrine adverse effects reported more often than placebo include gynecomastia and breast tenderness. Because it raises the testosterone:DHT ratio rather than lowering gonadal output, it does not require post-cycle 'recovery' in the anabolic-steroid sense.
Dose-related reductions in ejaculate volume, total sperm count, and sperm motility were seen in a 1-year RCT in healthy men; changes were mild and largely reversible after discontinuation, though motility reduction persisted at follow-up in some. Reduced libido, erectile dysfunction, and ejaculation disorders occur more than placebo and may persist in a subset. It is also a potent teratogen, causing abnormal development of male fetal genitalia; pregnant or potentially pregnant individuals must not take or handle the drug.
Depression, anxiety, and suicidal ideation have been reported in a subset of 5-alpha-reductase inhibitor users; depression is listed on product labeling. Evidence is largely observational/case-based and confounded, but the association (including persistence after stopping) is repeatedly described for dutasteride and finasteride.
No clinically important renal effects and negligible renal excretion of parent drug; no dose adjustment for renal impairment is described in the trial literature. No adequate signal of nephrotoxicity.
No clinically significant hematologic toxicity reported. It does not raise hematocrit (unlike androgens). Note: because the drug can be transferred in semen and is teratogenic, blood/semen donation is deferred during use and for a washout period; PSA (a chemistry, not hematology test) is roughly halved.
Primarily used to treat a dermatologic condition (androgenetic alopecia). Adverse dermatologic effects are uncommon; rare hypersensitivity reactions (rash, pruritus, urticaria, angioedema) have been reported in pharmacovigilance/labeling. No robust RCT-quantified dermatologic harm.
HPTA suppression & recovery
Suppression: None / not applicable — dutasteride does not suppress the hypothalamic-pituitary-testicular axis
Dutasteride blocks peripheral testosterone-to-DHT conversion; it lowers DHT ~90-95% while serum testosterone rises transiently rather than falling, so it does not cause the gonadal shutdown seen with anabolic steroids or SARMs and does not call for SERM-based restart therapy. It is not a SERM, and no SERM-based post-cycle protocol is described or endorsed here. The relevant recovery concern is different: a subset of users report sexual dysfunction (and mood symptoms) that can persist for months after stopping. Anyone with persistent sexual, mood, or fertility problems after discontinuation should be evaluated by an endocrinologist (and, for fertility, a reproductive specialist); do not self-manage hormones.
Monitoring
Cadence: Establish baseline before starting; re-baseline PSA at approximately 6 months (any confirmed rise on treatment should trigger prostate evaluation, not reassurance); thereafter monitor PSA and clinical status at least annually or per treating clinician. Symptom-driven labs (LFTs, hormones, semen analysis) as needed.
- New or worsening breathlessness, ankle/leg swelling, or exertional fatigue (possible cardiac failure)
- Confirmed rising PSA on treatment (possible occult prostate cancer)
- Breast lump, tenderness, or nipple discharge (gynecomastia; rarely male breast cancer)
- New or worsening depression, anxiety, or suicidal thoughts
- Persistent sexual dysfunction or reduced fertility
- Signs of hypersensitivity: rash, itching, swelling of face/lips, difficulty breathing
Contraindications
- Pregnancy or possibility of pregnancy — potent teratogen (abnormal male fetal genital development); pregnant/potentially pregnant persons must not use or even handle capsules
- Women of childbearing potential and children
- Known hypersensitivity to dutasteride, other 5-alpha-reductase inhibitors, or capsule components
- Severe hepatic impairment (no adequate data; expected higher exposure)
- Caution with strong CYP3A4 inhibitors (can raise exposure) and in men with pre-existing heart failure given the cardiac-failure signal
- Relative caution in men concerned about high-grade prostate cancer risk and in those who need reliable PSA-based cancer screening (PSA is ~halved)
Interaction profile
- ModerateWith another 5α-reductase inhibitor: Hormonal
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- This is educational reference material, not a recommendation to use; any use should be supervised by a clinician with baseline and periodic bloodwork.
- Never use or handle capsules if you are or might become pregnant, or if a pregnant person could contact the drug — it causes male fetal birth defects. Store securely away from pregnant household members.
- Tell any clinician ordering a PSA that you take dutasteride: it roughly halves PSA, so establish a new on-treatment baseline (~6 months) and treat any confirmed rise as a red flag warranting prostate evaluation, not reassurance.
- Do not donate blood or semen while taking dutasteride and for the washout period after stopping, because it is teratogenic and transferable.
- Stop and seek medical care for: new or worsening breathlessness, ankle swelling, or exertional fatigue (possible cardiac failure signal); breast lumps, pain, or nipple discharge (evaluate for gynecomastia and, rarely, male breast cancer); or signs of hypersensitivity (rash, swelling, trouble breathing).
- Because of the very long half-life, effects and side effects resolve slowly over weeks to months after stopping — do not expect rapid reversal.
- If sexual dysfunction, low mood, suicidal thoughts, or fertility problems appear and persist, stop and consult a clinician; involve an endocrinologist for hormonal symptoms and a reproductive specialist for fertility. Seek urgent help for suicidal ideation.
- Avoid combining with strong CYP3A4 inhibitors without clinician review, as they can raise dutasteride exposure.
- This monograph does not describe or endorse any dosing-to-maximize, SERM/dual-SERM protocols, or ways to obtain the drug.
Citations (11)
Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.
- 01
Dutasteride is a dual type 1/2 5-alpha-reductase inhibitor that reduces serum DHT by >90% and improves BPH symptoms, flow, and prostate volume while reducing acute urinary retention; gynecomastia, impotence, reduced libido, and ejaculation disorders occur more than placebo.
ReviewPMID 14565784 ↗
- 02
Dutasteride lowers DHT ~94% and produces mild, largely reversible reductions in ejaculate volume, total sperm count, and sperm motility; testosterone rises transiently.
- 03
Dutasteride has a long half-life (~7-9 days single-dose) requiring ~28-day washout in bioequivalence studies.
- 04
Dutasteride pharmacokinetics (AUC, Cmax) and metabolic clearance were characterized in healthy men; tamsulosin did not alter dutasteride exposure.
- 05
Meta-analysis of 9 RCTs: dutasteride improves IPSS, Qmax, and prostate volume in BPH but causes more drug-related adverse events than placebo.
Meta-analysisPMID 24500194 ↗
- 06
In the 4-year REDUCE RCT, dutasteride reduced biopsy-detected prostate cancer ~23% but showed an excess of Gleason 8-10 tumors in years 3-4 (12 vs 1, P=0.003) and a higher composite cardiac-failure rate (0.7% vs 0.4%, P=0.03); it also reduced acute urinary retention.
- 07
In CombAT, a 4-year RCT, dutasteride/tamsulosin improved BPH outcomes but showed an unexplained imbalance in the composite cardiac-failure term.
- 08
Heavy alcohol intake negated dutasteride's protective association against high-grade prostate cancer within the REDUCE trial population.
- 09
In a 24-week active/placebo-controlled RCT, dutasteride 0.5 mg dose-dependently increased hair count and width in male androgenetic alopecia and outperformed finasteride 1 mg on several endpoints.
- 10
Systematic review of 5-alpha-reductase inhibitor adverse effects: sexual dysfunction reported in ~3.4-15.8% of men, depression listed as a labeled effect, and teratogenic risk (male fetal birth defects) in pregnancy.
ReviewPMID 27672412 ↗
- 11
Persistent sexual dysfunction and reports of depression, anxiety, and suicidal ideation in a subset of users are described for finasteride and dutasteride (post-finasteride syndrome literature).
ReviewPost-finasteride syndrome: a surmountable challenge for cliniciansPMID 32033719 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice